Navigation Links
Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
Date:11/17/2010

GENEVA and RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2010 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented an update to the World Health Organization (WHO) on the development of the company's lead antiviral compound, CMX001, at the 12th Meeting of the WHO Advisory Committee on Variola Virus Research in a presentation titled "Status of CMX001 for Smallpox and Other dsDNA Viruses."  CMX001 is being developed for dual-use as a medical countermeasure in the event of a smallpox release and as a broad-spectrum antiviral for the treatment of life-threatening viruses in immunocompromised transplant and cancer patients.

"Chimerix is passionate about the need to develop effective antiviral therapeutics to improve global health and protect against viral threats such as smallpox.  Therefore, we are pleased by the opportunity to provide an update to the World Health Organization on the significant progress being made in the development of CMX001 as a potential dual-use agent," commented Wendy Painter, M.D., M.P.H., Chief Medical Officer of Chimerix.  "In addition to proven efficacy in numerous animal studies against pox viruses, we are amassing a significant body of clinical data in critically-ill patients regarding CMX001's safety and antiviral activity against double-stranded DNA viruses."

CMX001 is currently in Phase 2 clinical trials for prophylaxis of human cytomegalovirus infection and under development using the FDA's "Animal Rule" for smallpox infection.  It has proven effective in reduction of morbidity and mortality in animal models of smallpox, even when treatment is initiated after the onset of lesions.

CMX001 has a number of advantages over other drugs in development for treatment of smallpox, including: broad-spectrum inhibition of double-stranded DNA (dsDNA) viruses that cause human disease; a high barrier to resistance; convenient oral administrati
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
2. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
3. Chimerix to Present at Upcoming Investor Conferences
4. Chimerix Initiates Phase 1 Study of CMX157
5. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
6. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
7. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
8. Chimerix Joins International Network of Organizations to Cure Malaria
9. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
10. Aeterna Zentaris Presents Encouraging Preclinical Data on Two Novel Orally Active Anti-Cancer Compounds at Major Conference in Germany
11. Oramed Pharmaceuticals Presents Results of its Phase IIb Clinical Trial at the Diabetes Technology Meeting 2010 in Bethesda, MD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 Lancée par ... en décembre 2011, l,étude collaborative française ... qui compare   l es microsphères en ... dans le carcinome hépatocellulaire avancé, a recruté plus ... avancé   ; les résultats sont attendus fin ...
(Date:3/3/2015)... , March 3, 2015 NASA astronaut ... launch this month to spend a year living and working ... satellite interviews from 5:30 to 7 a.m. EDT Monday, March ... as he completes the final weeks of his ... a video on NASA Television highlighting his mission training and ...
(Date:3/3/2015)... 3, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... President and Chief Executive Officer of Neurocrine Biosciences, will ... Miami.   The live presentation takes place ... The presentation will be webcast and may be accessed ... Listeners are encouraged to visit the website ...
(Date:3/3/2015)... Crown Bioscience, Inc., a leading global drug ... Life Science division specializing in in vivo and in ... first products released include in vivo grade human and ... released in vivo grade monoclonal antibodies against PD-L1 and ... science portfolio with additional antibody products as well as ...
Breaking Biology Technology:Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2Crown Bioscience Launches Life Science Product Catalog 2
... at ... Nanopatterning Leader, AUSTIN, Texas, July 1 ... solutions, today,announced that Ben Eynon and Paul Hofemann have joined its ... of marketing and business development for semiconductors, and,vice president of marketing ...
... Trials ... of Drug Development, HAMILTON, N.J., July 1 ... today that it has,closed a $20 million financing by ... developed an innovative platform to centralize and,calibrate the assessment ...
... Inc. (Nasdaq: MGRM ) announced today that William ... update on the company,s business,at the Collins Stewart LLC ... 9:00 a.m. (Eastern Time) at the Mandarin Oriental Hotel ... broadcast or the subsequent archived,recording, log on to ...
Cached Biology Technology:Industry Veterans Join Molecular Imprints' Management Team 2Industry Veterans Join Molecular Imprints' Management Team 3MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures 2MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures 3MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures 4Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference 2
(Date:2/5/2015)... FRANCISCO , January 28, 2015 ... Market Analysis, Size And Segment Forecasts To 2020 has ... global IR camera market is expected to reach USD ... by Grand View Research, Inc. IR cameras help identify ... and are expected to witness surging demand in medical ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
(Date:1/22/2015)... MADISON, Wis. , Jan. 15, 2015  BellBrook ... for drug discovery, announced the launch of a ... of the company,s Transcreener UDP Assay, a high ... enzymes. The new assay will allow for sensitive ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... Our genes control many aspects of who we are ... certain diseases but how are the genes, and consequently ... have discovered a new group of molecules which control some ... the key to developing new therapies for treating neurodegenerative diseases. ...
... assistant professor in the Department of Chemistry and Biochemistry ... Faculty Early Career Development Award from the National Science ... modeling methods to study the biophysics of model cell ... award also will support the purchase of a computer ...
... JUPITER, FL, April 27, 2012 A scientist from ... been awarded $1.5 million from the National Institutes of ... new therapeutics targeting RNA., Matthew Disney, an associate professor ... four-year study. , RNA was once considered a passive ...
Cached Biology News:Doubling the information from the double helix 2Patel recognized with NSF Career Award for computer-modeling research on cell membranes 2Patel recognized with NSF Career Award for computer-modeling research on cell membranes 3
... Ambions 96 well Magnetic-Ring Stand is designed ... well U-bottom microplates. The stand has a ... well microtiter plate footprint. The use of ... fast and easy magnetic separation. With this ...
6B9...
Request Info...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
Biology Products: